NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

We announced to the SCI community that we will cover the cost of travel and accommodation for participants during the 16-week trial," said Mike Kelly, NervGen's President & CEO. "These initiatives are ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...

In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain. Never miss a story ...

Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure? Finding the cure to Alzheimer’s has confounded researchers for decades. As a disease, Alzheimer ...

So should NervGen Pharma ( CVE:NGEN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...